Nuclear Medicine Imaging and Therapy in Prostate Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 193
Special Issue Editors
Interests: nucleare medicine; PET/CT; SPECT/CT; radionuclide therapy
Special Issues, Collections and Topics in MDPI journals
Interests: molecular imaging; nuclear medicine; lung cancer; prostate cancer; neuroendocrine tumors; PET/CT; PET/MRI; lymphoma; radioligand therapy
Special Issues, Collections and Topics in MDPI journals
Interests: molecular imaging; PET; breast cancer; prostate cancer; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit a manuscript to this Special Issue of Diagnostics entitled “Nuclear Medicine Imaging and Therapy in Prostate Cancer”. Prostate cancer is the most common non-cutaneous malignancy among men and is an urgent public health issue.
Nuclear medicine imaging plays a key role in many clinical settings of prostate cancer, with numerous radiotracers available or under investigation. Such advancements in diagnostic imaging and therapy, together with the introduction of artificial intelligence technology in clinical practice, will accelerate the advent of true personalized medicine.
In this Special Issue of Diagnostics, we plan to address the complexity of molecular imaging and theranostics in prostate cancer. We prioritize high-quality original studies, encourage the submission of multidisciplinary works, and welcome well-designed meta-analyses and reviews.
Dr. Laura Evangelista
Dr. Priscilla Guglielmo
Dr. Luca Urso
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- 18F-FDG PET/CT or PET/MRI
- 68Ga-PSMA PET/CT or 18F-PSMA PET/CT or PET/MRI
- 18F-choline PET/CT
- 18F-FACBC
- theranostics
- beta-based therapy
- alpha-based therapy
- radiomics and artificial intelligence
